Rock Springs Capital Management LP Buys 150,336 Shares of Compass Therapeutics, Inc. (NASDAQ:CMPX)

Rock Springs Capital Management LP increased its holdings in Compass Therapeutics, Inc. (NASDAQ:CMPX - Free Report) by 2.7% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 5,779,575 shares of the company's stock after purchasing an additional 150,336 shares during the quarter. Rock Springs Capital Management LP owned 4.20% of Compass Therapeutics worth $8,380,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors also recently modified their holdings of CMPX. Tower Research Capital LLC TRC increased its position in shares of Compass Therapeutics by 298.0% in the fourth quarter. Tower Research Capital LLC TRC now owns 17,251 shares of the company's stock valued at $25,000 after acquiring an additional 12,917 shares during the period. Independent Advisor Alliance bought a new position in Compass Therapeutics during the 4th quarter valued at approximately $26,000. Mariner LLC purchased a new stake in Compass Therapeutics in the 4th quarter worth approximately $30,000. XTX Topco Ltd bought a new stake in shares of Compass Therapeutics in the 3rd quarter worth approximately $37,000. Finally, Sequoia Financial Advisors LLC purchased a new position in shares of Compass Therapeutics during the fourth quarter valued at approximately $45,000. Institutional investors own 68.43% of the company's stock.

Analysts Set New Price Targets

A number of research firms recently issued reports on CMPX. Guggenheim reissued a "buy" rating on shares of Compass Therapeutics in a research note on Tuesday. Jefferies Financial Group raised their price objective on Compass Therapeutics from $7.00 to $8.00 and gave the company a "buy" rating in a research report on Monday, February 10th. D. Boral Capital reissued a "buy" rating and issued a $32.00 target price on shares of Compass Therapeutics in a report on Monday. Wedbush reissued an "outperform" rating and issued a $8.00 target price on shares of Compass Therapeutics in a research note on Tuesday, April 1st. Finally, Leerink Partnrs upgraded shares of Compass Therapeutics from a "hold" rating to a "strong-buy" rating in a research note on Tuesday, April 1st. Eight research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat.com, Compass Therapeutics presently has an average rating of "Buy" and an average target price of $13.38.

Compass Therapeutics Price Performance

Compass Therapeutics stock traded up $0.09 during mid-day trading on Wednesday, reaching $2.07. 950,418 shares of the stock traded hands, compared to its average volume of 869,816. The stock has a market capitalization of $286.25 million, a PE ratio of -5.59 and a beta of 1.40. The business's 50-day moving average is $2.28 and its 200-day moving average is $2.09. Compass Therapeutics, Inc. has a 12-month low of $0.77 and a 12-month high of $4.08.

Compass Therapeutics (NASDAQ:CMPX - Get Free Report) last announced its earnings results on Thursday, February 27th. The company reported ($0.11) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.10) by ($0.01). Equities analysts anticipate that Compass Therapeutics, Inc. will post -0.36 EPS for the current fiscal year.

Insider Transactions at Compass Therapeutics

In other Compass Therapeutics news, insider Jonathan Anderman purchased 20,000 shares of the business's stock in a transaction on Monday, April 7th. The stock was acquired at an average price of $1.54 per share, for a total transaction of $30,800.00. Following the purchase, the insider now owns 21,000 shares of the company's stock, valued at approximately $32,340. This represents a 2,000.00 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Carl L. Gordon sold 3,571,428 shares of the business's stock in a transaction dated Wednesday, April 9th. The shares were sold at an average price of $1.59, for a total value of $5,678,570.52. The disclosure for this sale can be found here. 28.50% of the stock is currently owned by company insiders.

Compass Therapeutics Company Profile

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.